Lunit's AI Biomarker Analysis 'Lunit Scope' "Continuous Increase in Big Pharma Requests"

Medical AI company Lunit announced on the 29th that the number of research analysis service requests from global pharmaceutical companies for its AI biomarker platform, Lunit Scope, has surpassed 5,000 cases as of this month.

Lunit's artificial intelligence (AI) biomarker platforms 'Lunit Scope IO' (left) and 'Lunit Scope PD-L1'
[Photo by Lunit]

Lunit Scope is a solution that analyzes cancer patients' tissue slides using AI to predict patient responses to immune checkpoint inhibitors. Utilizing Lunit Scope is said to reduce clinical costs involved in new drug development for pharmaceutical companies while increasing the therapeutic response rate of drugs.

Lunit has identified that requests for patient tissue slide analysis from global pharmaceutical companies, which began at the end of last year, are continuously increasing. Tissue slide samples sent from big pharma companies based in the US and Europe are analyzed through overseas Lunit Scope servers. The analysis results are used solely for research purposes (RUO). Currently, Lunit is conducting studies with multiple pharmaceutical companies to verify the utility of Lunit Scope in this manner, and these are recorded as Lunit's 'research sales.'

The milestone of surpassing 5,000 cases includes requests received from numerous pharmaceutical companies, including seven multinational big pharma companies. Calculating the business days up to the end of this month, it is reported that more than 30 analyses have been conducted on average per day.

Additionally, Lunit explained that it has signed additional analysis contracts with multiple global pharmaceutical companies this year, and existing partner pharmaceutical companies are significantly expanding the number of analyses. In particular, interest and collaboration inquiries from major cancer research institutions, including the US non-profit cancer research organization 'Friends of Cancer Research (FOCR),' are increasing, suggesting that the application of Lunit Scope will expand further.

Seobum Seok, CEO of Lunit, said, "The one-time milestone sales that accounted for most of Lunit Scope's revenue until last year are now being replaced by research sales, forming a more solid revenue structure. Lunit Scope is providing new opportunities to pharmaceutical companies not only in immune checkpoint inhibitors but also in various anticancer drug development areas such as antibody-drug conjugates (ADC). If it obtains approval as an anticancer drug and companion diagnostic (CDx) model in the future, the sales scale will increase dramatically, incomparable to the current level."

This content was produced with the assistance of AI translation services.